DexCom (DXCM) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
DexCom (DXCM) has outperformed TransMedics Group (TMDX) over the past year, gaining 24.5% versus a loss of 33.1%. Over five years, TMDX leads with a +197.6% price change compared with -38.0% for DXCM. DexCom is the larger company by market cap ($31.85 billion vs $2.74 billion), about 11.6 times the size, while TransMedics Group is growing revenue faster (+37.1% vs +15.6%).
On valuation, DexCom trades at a lower forward P/E (27.0x vs 35.0x for TransMedics Group). TransMedics Group converts more of its revenue into profit, with a net margin of 31.4% versus 17.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXCM | TMDX |
|---|---|---|
| Share price | $84.41 | $79.00 |
| Market cap | $31.85B | $2.74B |
| 1-day change | +0.13% | -2.55% |
| YTD return | +27.18% | -35.06% |
| 1-year return | +24.54% | -33.08% |
| 5-year return | -37.99% | +197.55% |
| P/E ratio (TTM) | 33.50 | 21.01 |
| Forward P/E | 26.99 | 35.05 |
| EPS (TTM) | $2.52 | $3.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.66B | $605.49M |
| Revenue growth (YoY) | +15.60% | +37.13% |
| Net income (latest FY) | $836.30M | $190.29M |
| Gross margin | 60.10% | 59.92% |
| Operating margin | 19.56% | 17.93% |
| Net margin | 17.94% | 31.43% |
| 52-week high | $92.59 | $156.00 |
| 52-week low | $54.11 | $60.11 |
| Distance from 52-week high | -8.83% | -49.36% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +14.00% | +26.35% |
| Average volume | 4.43M | 820.41K |
| Shares outstanding | 377.36M | 34.68M |
| Employees | 11,000 | 898 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DexCom is about 11.6 times larger than TransMedics Group by market value ($31.85B vs $2.74B).
- DXCM has outperformed TMDX by 57.6 percentage points over the past year.
- DexCom trades at a higher earnings multiple (33.5x vs 21.0x trailing P/E).
- TransMedics Group is more profitable, keeping 31.4 cents of every revenue dollar as net income versus 17.9 cents for DexCom.
- TransMedics Group grew revenue faster in its latest fiscal year (+37.13% vs +15.60%).
About DexCom
DXCM stock →DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Healthcare · Medical Devices · 11,000 employees
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Healthcare · Medical Devices · 898 employees
DXCM vs TMDX FAQ
Which is bigger, DexCom or TransMedics Group?
DexCom (DXCM) is larger, with a market capitalization of $31.85B compared with $2.74B for TransMedics Group (TMDX).
Which stock has performed better over the past year, DXCM or TMDX?
DXCM returned +24.54% over the past 12 months, compared with -33.08% for TMDX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DXCM or TMDX?
TMDX has the lower trailing P/E at 21.0, versus 33.5 for DXCM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are DexCom and TransMedics Group in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.